Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas

[1]  M. Rijn,et al.  Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value , 2015, Histopathology.

[2]  K. Knobeloch,et al.  Selective inactivation of USP18 isopeptidase activity in vivo enhances ISG15 conjugation and viral resistance , 2015, Proceedings of the National Academy of Sciences.

[3]  J. Casanova,et al.  Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation , 2014, Nature.

[4]  K. S. Hall,et al.  Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  K. Yui.  Cross-presentation of malaria antigen by brain microvessels: why CD8+ T cells are critical for the pathogenesis of experimental cerebral malaria , 2013, EMBO molecular medicine.

[6]  S. Kotenko,et al.  Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10 , 2013, EMBO molecular medicine.

[7]  V. Huff,et al.  Ubiquitin specific protease 18 (Usp18) is a WT1 transcriptional target. , 2013, Experimental cell research.

[8]  N. Salemis.  Recurrent subcutaneous trunk leiomyosarcoma: Management and review of the literature , 2013, Journal of natural science, biology, and medicine.

[9]  David M. Thomas,et al.  Targeted therapies: Pazopanib for soft-tissue sarcoma: a PALETTE of data emerges , 2012, Nature Reviews Clinical Oncology.

[10]  E. Dmitrovsky,et al.  Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target , 2012, Molecular Cancer Therapeutics.

[11]  Andrew H. Beck,et al.  Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma , 2012, Proceedings of the National Academy of Sciences.

[12]  Marc Ladanyi,et al.  Advances in sarcoma genomics and new therapeutic targets , 2011, Nature Reviews Cancer.

[13]  David M. Thomas,et al.  Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis , 2010, Clinical Cancer Research.

[14]  E. Dmitrovsky,et al.  Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia. , 2010, Cancer research.

[15]  F. Chibon,et al.  Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. , 2010, The American journal of pathology.

[16]  D. Malo,et al.  N-Ethyl-N-Nitrosourea–Induced Mutation in Ubiquitin-Specific Peptidase 18 Causes Hyperactivation of IFN-αβ Signaling and Suppresses STAT4-Induced IFN-γ Production, Resulting in Increased Susceptibility to Salmonella Typhimurium , 2010, The Journal of Immunology.

[17]  D. Kirsch,et al.  Animal models of soft-tissue sarcoma , 2010, Disease Models & Mechanisms.

[18]  M. Sperl,et al.  Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  P. Gosset,et al.  Imaging of the most frequent superficial soft-tissue sarcomas , 2011, Skeletal Radiology.

[20]  B. Vanderhyden,et al.  Conditional Inactivation of Brca1, p53 and Rb in Mouse Ovaries Results in the Development of Leiomyosarcomas , 2009, PloS one.

[21]  Herbert S Schwartz,et al.  Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma , 2009, Modern Pathology.

[22]  E. Podack,et al.  A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas , 2009, British Journal of Cancer.

[23]  Fabrizio Galimberti,et al.  Uncovering Growth-Suppressive MicroRNAs in Lung Cancer , 2009, Clinical Cancer Research.

[24]  A. Sorkin,et al.  RNA interference screen identifies Usp18 as a regulator of epidermal growth factor receptor synthesis. , 2009, Molecular biology of the cell.

[25]  J. Blay,et al.  Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  P. Pandolfi,et al.  The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas , 2007, Nature Medicine.

[27]  M. Shago,et al.  Characterization of trisomy 8 in pediatric undifferentiated sarcomas using advanced molecular cytogenetic techniques. , 2007, Cancer genetics and cytogenetics.

[28]  M. Weiser-Evans,et al.  Unique, Highly Proliferative Growth Phenotype Expressed by Embryonic and Neointimal Smooth Muscle Cells Is Driven by Constitutive Akt, mTOR, and p70S6K Signaling and Is Actively Repressed by PTEN , 2004, Circulation.

[29]  T. Ludwig,et al.  A mouse model of uterine leiomyosarcoma. , 2004, The American journal of pathology.

[30]  P. Meltzer,et al.  Mechanisms of sarcoma development , 2003, Nature Reviews Cancer.

[31]  C. Antonescu,et al.  Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Meltzer,et al.  Soft tissue sarcomas of adults: state of the translational science. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  Ming Yan,et al.  Protein ISGylation modulates the JAK-STAT signaling pathway. , 2003, Genes & development.

[34]  S. Orkin,et al.  Dysregulation of protein modification by ISG15 results in brain cell injury. , 2002, Genes & development.

[35]  Dong-er Zhang,et al.  UBP43 (USP18) Specifically Removes ISG15 from Conjugated Proteins* , 2002, The Journal of Biological Chemistry.

[36]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[37]  F. Collin,et al.  Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas , 2001, Cancer.

[38]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[39]  A. Afify,et al.  Trisomy 8 in embryonal rhabdomyosarcoma detected by fluorescence in situ hybridization. , 1999, Cancer genetics and cytogenetics.

[40]  M. van Glabbeke,et al.  Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  E. Dmitrovsky,et al.  Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation. , 1996, Oncogene.

[42]  C. Kozak,et al.  Isolation and genetic mapping of two novel members of the murine Wnt gene family, Wnt11 and Wnt12, and the mapping of Wnt5a and Wnt7a. , 1994, Genomics.

[43]  C. Fletcher,et al.  Leiomyoma of Deep Soft Tissue: Clinicopathologic Analysis of a Series , 1994, The American journal of surgical pathology.

[44]  K. Loeb,et al.  The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. , 1992, The Journal of biological chemistry.

[45]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[46]  A. Illiano,et al.  [Sarcoma of the soft tissues]. , 1983, Archivio Monaldi per la tisiologia e le malattie dell'apparato respiratorio.

[47]  P. Lengyel,et al.  Accumulation of an mRNA and protein in interferon-treated Ehrlich ascites tumour cells , 1979, Nature.

[48]  J. Budd.  Sarcoma of soft tissues. , 1947, California medicine.